Delving into the Latest Updates on CK15 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

VDR

Mechanism

VDR modulators(Vitamin D receptor modulators)

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication

Chronic Kidney DiseasesHyperparathyroidism, SecondaryNephrosis

Inactive Indication

Kidney Failure, Chronic

Originator Organization

Vidasym, Inc.

Active Organization

Xinkai Medicine and Chemical Intermediates (Shanghai) Co., Ltd.Xinkaiyiyao Science & Technology Shanghai Co. Ltd.

Inactive Organization

Vidasym, Inc.

Drug Highest PhasePhase 2

First Approval Date-

RegulationSpecial Review Project (CN)

Login to view timeline

Structure

Molecular FormulaC27H44O4

InChIKeyUECLGFUOBJOZRT-PIOAYZOASA-N

CAS Registry1469985-12-3

1. To evaluate the safety and efficacy of oral administration of different doses of CK15 soft capsules for 4 consecutive weeks in the treatment of patients with chronic kidney disease stage 5 undergoing hemodialysis and SHPT 2. To evaluate the PK characteristics of CK15 soft capsules in patients with chronic kidney disease stage 5 undergoing hemodialysis 3. To provide a basis for determining the dosing regimen and dosage for Phase II clinical trials

Start Date14 Jun 2021

Sponsor / Collaborator

Xinkai Medicine and Chemical Intermediates (Shanghai) Co., Ltd.

[+1]

CTR20191150 / RecruitingPhase 1

CK15软胶囊在健康受试者中单剂量及多剂量给药的安全性、药代动力学和药效动力学以及进食影响研究

[Translation] Safety, pharmacokinetics, pharmacodynamics and food effect of single-dose and multiple-dose CK15 soft capsules in healthy subjects

1.评价CK15软胶囊在健康受试者中单剂量给药和多剂量给药的安全性及耐受性 2.明确CK15软胶囊的安全剂量范围 3.评价CK15软胶囊在健康受试者中的药代动力学及药效动力学特征 4.评价进食对CK15软胶囊在健康受试者中的药代动力学特征的影响

[Translation]

1. Evaluate the safety and tolerability of single-dose and multiple-dose CK15 soft capsules in healthy subjects 2. Determine the safe dose range of CK15 soft capsules 3. Evaluate the pharmacokinetic and pharmacodynamic characteristics of CK15 soft capsules in healthy subjects 4. Evaluate the effect of food intake on the pharmacokinetic characteristics of CK15 soft capsules in healthy subjects

Start Date10 Jun 2019

Sponsor / Collaborator

Xinkai Medicine and Chemical Intermediates (Shanghai) Co., Ltd.

[+1]

100 Clinical Results associated with CK15

Login to view more data

100 Translational Medicine associated with CK15

Login to view more data

100 Patents (Medical) associated with CK15

Login to view more data

14

Literatures (Medical) associated with CK15

20 May 2023·World journal of microbiology & biotechnology

Enhancing wuyiencin productivity of Streptomyces albulus (CK15) by mutagenesis breeding with atmospheric and room temperature plasma.

Article

Author: Liu, Binghua ; Ge, Beibei ; Shi, Liming ; Thein, Yu Wah ; Zhang, Kecheng ; Wei, Qiuhe

Streptomyces species are known for their ability to efficiently produce secondary metabolites, including various antibiotics. Wuyiencin, an antibiotic produced by Streptomyces albulus CK15, is commonly used in agriculture to control fungal diseases in crops and vegetables. In this study, we utilized atmospheric and room temperature plasma (ARTP) mutagenesis to generate mutant S. albulus strains with improved fermentation capabilities for wuyiencin production. After mutagenizing the wild-type S. albulus CK15 strain once and conducting two rounds of antimicrobial screening, three genetically stable mutants (M19, M26, and M28) were identified. These mutants showed increased wuyiencin production by 17.4%, 13.6%, and 18.5% in comparison to the CK15 strain in flask culture, respectively. The M28 mutant exhibited the highest wuyiencin activity, producing 1443.0 ± 134.6 U/mL in flask culture and 1673.8 ± 127.4 U/mL in a 5 L fermenter. These results demonstrate that ARTP is an efficient tool for microbial mutation breeding and improving wuyiencin production.

01 Jan 2023·Plant Disease

Induced Defense Response in Soybean to Sclerotinia sclerotiorum Using Wuyiencin from Streptomyces albulus CK-15

Article

Author: Zhang, Kecheng ; Yang, Miaoling ; Zhang, Wei ; Shi, Liming ; Ge, Beibei ; Lv, Zhaoyang

Sclerotinia sclerotiorum (Lib) de Bary, a destructive fungal pathogen with an extensive host range, causes major economic losses to crop production activities globally. Streptomyces spp. produce secondary metabolites with diverse structures and biological activities with potential applications in the control of crop disease. This study explored the potential application of wuyiencin, a secondary metabolite of Streptomyces albulus CK-15, to induce defense responses in soybean against S. sclerotiorum. Lesion size was reduced by nearly 60% in wuyiencin-treated soybean plants compared with plants infected with S. sclerotiorum only in greenhouse experiments. Wuyiencin induced callose deposition at 6 h postinoculation and increased reactive-oxygen-scavenging enzyme activities, including superoxide dismutase, catalase, and peroxidase. Moreover, wuyiencin inoculated before S. sclerotiorum infection significantly increased polyphenol oxidase, phenylalanine ammonia lyase, chitinase, and β-1,3-glucanase activity, suggesting their involvement in soybean defense responses to S. sclerotiorum. Further, qRT-PCR results showed expression levels of the hormone signaling markers CO11, MYC2, PR4, PR1, NPR1, and ERF1 were upregulated in infected leaves treated with wuyiencin.

01 Apr 2022·World Journal of Microbiology and BiotechnologyQ4 · ENGINEERING & TECHNOLOGY

Effect of toyF on wuyiencin and toyocamycin production by Streptomyces albulus CK-15

Q4 · ENGINEERING & TECHNOLOGY

Article

Author: Ge, Beibei ; Zhang, Kecheng ; Shi, Liming ; Liu, Binghua ; Wei, Qiuhe ; Yang, Miaoling

Streptomyces albulus CK-15 produces various secondary metabolites, including the antibiotics wuyiencin and toyocamycin, which can reportedly control a broad range of plant fungal diseases. The production of these nucleoside antibiotics in CK-15 is regulated by two biosynthesis gene clusters. To investigate the potential effect of toyocamycin biosynthesis on wuyiencin production, we herein generated S. albulus strains in which a key gene in the toyocamycin biosynthesis gene cluster, namely toyF, was either deleted or overexpressed. The toyF deletion mutant ∆toyF did not produce toyocamycin, while the production of wuyiencin increased by 23.06% in comparison with that in the wild-type (WT) strain. In addition, ΔtoyF reached the highest production level of wuyiencin 4 h faster than the WT strain (60 h vs. and 64 h). Further, toyocamycin production by the toyF overexpression strain was two-fold higher than by the WT strain, while wuyiencin production was reduced by 29.10%. qRT-PCR showed that most genes in the toyocamycin biosynthesis gene cluster were expressed at lower levels in ∆toyF as compared with those in the WT strain, while the expression levels of genes in the wuyiencin biosynthesis gene cluster were upregulated. Finally, the growth rate of ∆toyF was much faster than that of the WT strain when cultured on solid or liquid medium. Based on our findings, we report that in industrial fermentation processes, ∆toyF has the potential to increase the production of wuyiencin and reduce the timeframe of fermentation.

100 Deals associated with CK15

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 2	CN	Xinkaiyiyao Science & Technology Shanghai Co. Ltd.	14 Jun 2021
Chronic Kidney Diseases	Phase 2	CN	Xinkai Medicine and Chemical Intermediates (Shanghai) Co., Ltd.	14 Jun 2021
Hyperparathyroidism, Secondary	Phase 2	CN	Xinkaiyiyao Science & Technology Shanghai Co. Ltd.	14 Jun 2021
Hyperparathyroidism, Secondary	Phase 2	CN	Xinkai Medicine and Chemical Intermediates (Shanghai) Co., Ltd.	14 Jun 2021
Nephrosis	Phase 2	CN	Xinkaiyiyao Science & Technology Shanghai Co. Ltd.	14 Jun 2021
Nephrosis	Phase 2	CN	Xinkai Medicine and Chemical Intermediates (Shanghai) Co., Ltd.	14 Jun 2021
Kidney Failure, Chronic	Preclinical	US	Vidasym, Inc.	24 Jan 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


1R43AR065247 (ASN2014)	Not Applicable	Uremia	-	VS-105 0.05 μg/kg	jdusrmzaia(sxqncacnjy) = vbqshhtfje myzcyyrydt (depppvjddv )	Positive	11 Nov 2014
				VS-105 0.2 μg/kg	jdusrmzaia(sxqncacnjy) = hvjapxrhkx myzcyyrydt (depppvjddv )
ASN2013	Not Applicable	Uremia	-	VS-105	(pumiwzfnja) = nreevxasme fsewaosfwf (jlpgfvpuhm )	-	05 Nov 2013
				Enalapril	(pumiwzfnja) = ghicamuwdr fsewaosfwf (jlpgfvpuhm )